论文部分内容阅读
目的探讨血清趋化因子配体5(CXCL5)对膀胱癌患者外科治疗后复发的影响。方法选取收治的外科手术治疗的膀胱癌患者96例为研究对象,采用酶联免疫吸附法(ELISA),检测其中血清CXCL5水平,将CXCL5≤700pg/ml定义为阴性,CXCL5>700 pg/ml定义为阳性。结果 96例膀胱癌患者中CXCL5阳性者30例,占31.25%。CXCL5水平与TNM分期、病理类型、组织学分级和淋巴结转移相关(P<0.05),与年龄、性别、肿瘤大小无关(P>0.05)。CXCL5阳性和CXCL5阴性患者无瘤生存时间分别为41.5个月和55.2个月,5年无瘤生存率分别为26.67%(8/30)和57.58%(38/66),差异有统计学意义(P<0.05)。多变量COX回归分析表明:TNM分期、病理类型、淋巴结转移和CXCL5是膀胱癌患者术后复发的独立预测因素。结论膀胱癌患者血清CXCL5基线水平不但可以作为初步评估病情严重程度的指标,还可以作为术后复发的独立预测指标。
Objective To investigate the effect of serum chemokine ligand 5 (CXCL5) on the recurrence of bladder cancer after surgical treatment. Methods Ninety-six patients with bladder cancer treated by surgery were enrolled in the study. Serum levels of CXCL5 were detected by enzyme-linked immunosorbent assay (ELISA), CXCL5≤700 pg / ml was defined as negative, CXCL5> 700 pg / ml was defined Positive. Results There were 30 CXCL5 positive cases in 96 cases of bladder cancer, accounting for 31.25%. The level of CXCL5 correlated with TNM stage, pathological type, histological grade and lymph node metastasis (P <0.05), but not with age, sex and tumor size (P> 0.05). The tumor-free survival rates of patients with CXCL5-positive and CXCL5-negative patients were 41.5 months and 55.2 months, respectively. The 5-year disease-free survival rates were 26.67% (8/30) and 57.58% (38/66) respectively, with statistically significant differences P <0.05). Multivariable COX regression analysis showed that TNM staging, pathological type, lymph node metastasis and CXCL5 were independent predictors of postoperative recurrence in patients with bladder cancer. Conclusion The baseline level of serum CXCL5 in patients with bladder cancer can not only be used as an index to evaluate the severity of illness but also as an independent predictor of postoperative recurrence.